GLYBURIDE (MICRONIZED)
LOE ApproachingNDAORALTABLET
Approved
Apr 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Glyburide (micronized) is an oral sulfonylurea antidiabetic agent used to treat type 2 diabetes mellitus. The micronized formulation enhances bioavailability and allows for lower dosing compared to conventional glyburide. It works by stimulating insulin secretion from pancreatic beta cells.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), signaling potential team consolidation and transition focus toward lifecycle extension or portfolio rotation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on glyburide (micronized) offers limited growth trajectory given the LOE-approaching lifecycle and minimal linked job openings. Career value lies in expertise with mature product management, regulatory compliance, and transition planning rather than commercial expansion or innovation.
Regulatory Affairs SpecialistMedical Safety Officer
Worked on GLYBURIDE (MICRONIZED) at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.